- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06694155
Myseproteininntak og glukosekontroll hos personer før og etter diabetes (DAIRY)
To examine the effects of twice daily whey protein consumption on blood glucose and insulin in pre-diabetic and diabetic individuals
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Protein consumption in the morning has been shown to reduce appetite and caloric intake (19). In addition, premeal whey consumption reduces post prandial blood glucose, reduces gastric emptying rate, and increases peak blood insulin (10). Thus, it is proposed that ingestion of whey protein within 1hr of waking (and prior to breakfast) and 30 minutes prior to dinner will be more effective in suppressing appetite, carbohydrate intake, and glucose AUC. Ingestion upon waking will mitigate the cortisol-induced drive for carbohydrate intake. Ingestion prior to dinner, the most frequently consumed and largest meal in America (20), will reduce food intake, post meal blood glucose, and insulin area under the curve (21).
Specific Aims
- Determine the effect of WP ingestion within 1hr of waking and prior to breakfast, and 30min prior to dinner, on appetite suppression, carbohydrate and caloric intake, and 24hr glucose AUC over 7d in pre-diabetic (A1C 5.7%-6.4%) and diabetic (A1C 6.5%-7.5%) individuals.
- Determine the effect of WP ingestion within 1hr of waking and 30min prior to dinner on changes in OGTT, Matsuda index, and whole-body protein balance (compared to control) before and after 7d of WP consumption in pre-diabetic and diabetic individuals.
- Determine outcome differences between pre-diabetic and diabetic individuals.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Arny Ferrando, PhD
- Telefonnummer: 5015265711
- E-post: aferrando@uams.edu
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202
- Rekruttering
- University of Arkansas for Medical Sciences
-
Ta kontakt med:
- Samantha Seale, MS
- Telefonnummer: 5013207602
- E-post: sseale@uams.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Males and females ages 50-70 years.
- Body mass index between 25-45 kg/m2
- Capable of providing informed consent.
- COVID-19 negative and/or asymptomatic.
- Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions.
- HbA1c: 5.7-6.4% or 6.5% to 7.5% or fasting glucose ≥100 mg/dL
Exclusion Criteria:
- Subject who does not/will not eat dairy protein sources.
- Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants.
- Unwilling to keep a detailed 7 day food journal on two occasions
- Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team.
- Lactose intolerance.
- Hemoglobin <10g/dL at screening.
- History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
- History of gastrointestinal bypass/reduction surgery.
- Pregnant or lactating individuals.
- History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)
- Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
- Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.).
- Unwilling to avoid using protein or amino-acid supplements during participation.
- Unwilling to fast overnight.
- Any medical condition or medication that the PI or clinical study staff finds contradictory to this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Whey Protein Supplementation
Crossover study |
This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation. |
|
Placebo komparator: Placebo Supplementation
Crossover study |
1 week of Non-whey protein Placebo supplement |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Whole body protein turnover
Tidsramme: 7 days
|
Whole body protein turnover reflects the continual synthesis and breakdown of body proteins. It can be measured at a whole-body or tissue level using stable isotope methods. |
7 days
|
|
Oral Glucose Tolerance Test
Tidsramme: 7 days
|
Oral Glucose Tolerance Test (OGTT) is used to screen for or diagnose diabetes. Normal blood values for a 75 gram OGTT are: Fasting -- 60 to 99 mg/dL (3.3 to 5.5 mmol/L), 1 hour -- Less than 200 mg/dL (11.1 mmol/L), 2 hours -- Less than 140 mg/dL (7.8 mmol/L) is normal. |
7 days
|
|
Blood glucose
Tidsramme: 7 days
|
Continuous glucose monitoring means using a device to automatically estimate your blood glucose level, also called blood sugar, throughout the day and night for 7 days. |
7 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite Appetite Scale
Tidsramme: 7 days
|
A composite appetite scale is a measure used to assess appetite control and influence energy intake. It can be calculated based on factors such as hunger, desire to eat, and fullness rating. Appetite Scale: How Hungry do you feel? Not Hungry at all <---> Have never been more Hungry How Satisfied do you feel? Completely empty <----> Can't eat another bite How Full do you feel? Not full at all <----> Totally full The more a person is satisfied and feels full and less hungry, the better the outcome is for whey vs placebo supplementation. |
7 days
|
|
Dietary Intake Log
Tidsramme: 7 days
|
A dietary intake log, also known as a food diary, is a self-reported account of all foods and beverages consumed within a specific timeframe. |
7 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 297495
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .